Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | CNR1 | P21554 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219143 | 1.00 | CNR2 (0.66) | CNR2ALDH1A1BLMTDP1KCNK3 | |
| SCHEMBL12435696 | 0.96 | PLA2G10 (0.61) | CNR2ALDH1A1BLMTDP1KCNK3 | |
| SCHEMBL12435851 | 0.96 | PLA2G10 (0.61) | CNR2ALDH1A1BLMTDP1KCNK3 | |
| SCHEMBL7621368 | 0.92 | CNR1 (0.56) | CNR2ALDH1A1BLMTDP1KCNK3 | |
| SCHEMBL22341756 | 0.91 | CNR1 (0.72) | CNR2ALDH1A1BLMTDP1KCNK3 | |
| SCHEMBL15549066 | 0.89 | LPAR3 (0.61) | CNR2ALDH1A1BLMTDP1KCNK3 | |
| SCHEMBL14199487 | 0.88 | CNR1 (0.69) | CNR2ALDH1A1BLMTDP1KCNK3 | |
| SCHEMBL7769502 | 0.88 | PLA2G10 (0.70) | MEN1KMT2A | |
| SCHEMBL7769504 | 0.88 | PLA2G10 (0.70) | MEN1KMT2A | |
| SCHEMBL7769580 | 0.88 | PLA2G10 (0.70) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-16 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW (IL) | 2011-07-21 | — | — | US | disclosed |
| WO-2009109973-A2 | COMPOUNDS AND METHODS OF TREATING OBESITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309273-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | FABP4, LIPC, GPR119 | CNR2 374/4885ALDH1A1 939/4885BLM 4556/4885 |
| US-20110178151-A1 | COMPOUNDS AND METHODS OF TREATING OBESITY | GPR119, FABP4, LIPC | CNR2 276/4885ALDH1A1 933/4885BLM 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.